Kamila Pytel

Kamila Pytel is an experienced professional in the field of analytical development, specializing in AAV gene therapy products. Currently serving as Associate Director of CMC Analytical Development at Novartis UK from September 2022, Kamila leads a multi-functional analytical team focused on product characterization and quality control following the acquisition of Gyroscope Therapeutics. Prior experience includes holding the Associate Director position at Gyroscope Therapeutics, where responsibilities encompassed designing analytical laboratories and managing teams for AAV-derived product testing. Kamila has also contributed to Pfizer as a Senior Scientist by developing analytical assays for gene therapy targets and completed postdoctoral research at Imperial College London, participating as an invited speaker at notable conferences. Kamila’s career began at Prionics AG, where innovative methodologies for disease detection were developed. Kamila holds a PhD in Bio-medical Sciences from Aston University and a Master's degree in Molecular Biology from Jagiellonian University.